Truist Financial
BTAI icon

Truist Financial’s BioXcel Therapeutics BTAI Stock Holding History

Truist Financial’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-680
Closed -$6.64K – 2531
2024
Q3 		$6.64K Hold
680
– – ﹤0.01% 2488
2024
Q2 		$13.9K Hold
680
– – ﹤0.01% 2630
2024
Q1 		$30.7K Hold
680
– – ﹤0.01% 2594
2023
Q4 		$32.1K Buy
+680
New +$37.8K ﹤0.01% 2605
2023
Q3 		– Sell
-710
Closed -$75.6K – 2593
2023
Q2 		$75.6K Hold
710
– – ﹤0.01% 2527
2023
Q1 		$212K Sell
710
-36
-5% -$15.4K ﹤0.01% 2400
2022
Q4 		$256K Sell
746
-711
-49% -$172K ﹤0.01% 2301
2022
Q3 		$275K Buy
1,457
+209
+17% +$48.5K ﹤0.01% 2131
2022
Q2 		$264K Buy
1,248
+43
+4% +$9.04K ﹤0.01% 2293
2022
Q1 		$403K Buy
+1,205
New +$349K ﹤0.01% 2119
2020
Q4 		– Sell
-1,326
Closed -$920K – 2552
2020
Q3 		$920K Buy
1,326
+1,063
+404% +$798K ﹤0.01% 1407
2020
Q2 		$223K Buy
+263
New +$172K ﹤0.01% 2119

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Truist Financial's BTAI Position: Q4 2024 in Review

Truist Financial sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 680 shares — an estimated $6.64K sold.

Truist Financial first reported a position in BTAI in Q2 2020 and held it in 12 quarters. The position peaked at $920K in Q3 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

  • Truist Financial reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Truist Financial sold 680 BioXcel Therapeutics shares in Q4 2024, an estimated $6.64K.
  • Truist Financial first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 12 quarters.
  • Truist Financial's BioXcel Therapeutics position peaked at $920K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on Truist Financial's 13F filing for Q4 2024, filed 31 Jan 2025.